Researchers and global health agencies are rapidly deploying adaptive clinical trials in response to the latest Ebola outbreak in the Democratic Republic of the Congo (DRC), according to verified reports from the World Health Organization (WHO) and other sources as of May 28, 2026. The trials build on lessons learned from previous Ebola epidemics and the COVID-19 pandemic, aiming to accelerate the evaluation of treatments and vaccines.
The outbreak, declared in early May 2026 in the DRC's North Kivu province, has seen at least 12 confirmed cases and 6 deaths as of May 27, 2026, per WHO situation reports. Adaptive trial designs allow for real-time modifications based on interim results, potentially speeding up the identification of effective interventions.
Key partners include the DRC Ministry of Health, WHO, and the National Institute of Allergy and Infectious Diseases (NIAID). The trials will test multiple therapeutic candidates simultaneously, with a focus on monoclonal antibodies and antiviral drugs that showed promise in earlier outbreaks.
This approach mirrors strategies used during the COVID-19 pandemic, such as the WHO's Solidarity trials, and aims to reduce the time needed to approve effective treatments. The WHO has emphasized the importance of community engagement and ethical oversight in the DRC.
